B. Metzler seel. Sohn & Co. Holding AG Acquires Shares of 31,405 ACADIA Pharmaceuticals Inc. (NASDAQ:ACAD)

B. Metzler seel. Sohn & Co. Holding AG acquired a new stake in ACADIA Pharmaceuticals Inc. (NASDAQ:ACAD) in the 3rd quarter, HoldingsChannel reports. The fund acquired 31,405 shares of the biopharmaceutical company’s stock, valued at approximately $483,000.

A number of other hedge funds have also recently modified their holdings of the stock. Park Place Capital Corp acquired a new stake in ACADIA Pharmaceuticals during the third quarter valued at $25,000. Values First Advisors Inc. acquired a new stake in shares of ACADIA Pharmaceuticals during the 3rd quarter valued at about $27,000. Quest Partners LLC increased its stake in shares of ACADIA Pharmaceuticals by 42.3% in the 3rd quarter. Quest Partners LLC now owns 3,520 shares of the biopharmaceutical company’s stock valued at $54,000 after purchasing an additional 1,047 shares in the last quarter. Stonepine Capital Management LLC acquired a new position in ACADIA Pharmaceuticals in the 2nd quarter worth about $81,000. Finally, Mirae Asset Global Investments Co. Ltd. boosted its position in ACADIA Pharmaceuticals by 21.6% during the third quarter. Mirae Asset Global Investments Co. Ltd. now owns 5,999 shares of the biopharmaceutical company’s stock worth $94,000 after purchasing an additional 1,066 shares in the last quarter. Hedge funds and other institutional investors own 96.71% of the company’s stock.

ACADIA Pharmaceuticals Price Performance

Shares of ACAD stock opened at $16.37 on Monday. The company has a market capitalization of $2.72 billion, a PE ratio of 20.99 and a beta of 0.38. The firm’s 50-day moving average is $15.61 and its two-hundred day moving average is $15.97. ACADIA Pharmaceuticals Inc. has a 12 month low of $14.15 and a 12 month high of $32.59.

ACADIA Pharmaceuticals (NASDAQ:ACAD) last released its quarterly earnings data on Wednesday, November 6th. The biopharmaceutical company reported $0.20 EPS for the quarter, beating analysts’ consensus estimates of $0.14 by $0.06. The firm had revenue of $250.40 million for the quarter, compared to analysts’ expectations of $248.83 million. ACADIA Pharmaceuticals had a return on equity of 25.83% and a net margin of 13.83%. The firm’s quarterly revenue was up 18.3% on a year-over-year basis. During the same period in the prior year, the firm posted ($0.40) earnings per share. Sell-side analysts forecast that ACADIA Pharmaceuticals Inc. will post 0.72 EPS for the current year.

Analyst Ratings Changes

ACAD has been the subject of several research analyst reports. Needham & Company LLC reaffirmed a “buy” rating and set a $28.00 target price on shares of ACADIA Pharmaceuticals in a research note on Thursday, November 7th. Citigroup decreased their price objective on shares of ACADIA Pharmaceuticals from $30.00 to $23.00 and set a “buy” rating on the stock in a report on Thursday, August 8th. Cantor Fitzgerald cut their target price on shares of ACADIA Pharmaceuticals from $37.00 to $28.00 and set an “overweight” rating for the company in a research note on Wednesday, August 7th. Raymond James reaffirmed a “market perform” rating on shares of ACADIA Pharmaceuticals in a research note on Thursday, October 10th. Finally, Morgan Stanley lowered ACADIA Pharmaceuticals from an “overweight” rating to an “equal weight” rating and cut their price objective for the stock from $28.00 to $20.00 in a research note on Wednesday, August 7th. Six analysts have rated the stock with a hold rating and twelve have given a buy rating to the stock. According to MarketBeat.com, the stock has an average rating of “Moderate Buy” and an average target price of $25.56.

Insider Activity

In other ACADIA Pharmaceuticals news, COO Brendan Teehan sold 10,329 shares of the business’s stock in a transaction that occurred on Tuesday, November 19th. The stock was sold at an average price of $16.81, for a total value of $173,630.49. Following the sale, the chief operating officer now owns 62,105 shares of the company’s stock, valued at $1,043,985.05. The trade was a 14.26 % decrease in their ownership of the stock. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available through this link. Also, insider James Kihara sold 4,073 shares of the stock in a transaction dated Tuesday, November 19th. The stock was sold at an average price of $16.81, for a total value of $68,467.13. Following the transaction, the insider now directly owns 19,863 shares in the company, valued at approximately $333,897.03. The trade was a 17.02 % decrease in their position. The disclosure for this sale can be found here. Insiders have sold a total of 24,661 shares of company stock valued at $414,551 in the last quarter. Insiders own 28.30% of the company’s stock.

ACADIA Pharmaceuticals Profile

ACADIA Pharmaceuticals Inc, a biopharmaceutical company, focuses on the development and commercialization innovative medicines that address unmet medical needs in central nervous system (CNS) disorders and rare diseases in the United States. The company offers NUPLAZID (pimavanserin) for the treatment of hallucinations and delusions associated with Parkinson's disease psychosis; and DAYBUE, a novel synthetic analog of the amino-terminal tripeptide of insulin-like growth factor 1 for treatment of Rett Syndrome.